Diabetes Is Reversed in a Murine Model by Marginal Mass Syngeneic Islet Transplantation Using a Subcutaneous Cell Pouch Device
| Autor: | Rena Pawlick, A. MacGillivary, Boris Gala-Lopez, Philip M. Toleikis, David J. G. White, A. M. James Shapiro, Delfina M. Mazzuca, Andrew R. Pepper |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Blood Glucose
Male Pancreas Artificial endocrine system Pathology medicine.medical_specialty Time Factors endocrine system diseases medicine.medical_treatment Islets of Langerhans Transplantation Neovascularization Physiologic Diabetes Mellitus Experimental Islets of Langerhans Original Basic Science—General Diabetes mellitus medicine Insulin Animals Mice Inbred BALB C Transplantation Type 1 diabetes geography geography.geographical_feature_category Bioartificial Organs business.industry Pancreatic islets Equipment Design Glucagon medicine.disease Islet Transplantation Isogeneic surgical procedures operative Diabetes Mellitus Type 1 medicine.anatomical_structure Microvessels Immunology Stem cell business Pancreas |
| Zdroj: | Transplantation |
| ISSN: | 0041-1337 |
| Popis: | Background Islet transplantation is a successful β-cell replacement therapy for selected patients with type 1 diabetes mellitus. Although high rates of early insulin independence are achieved routinely, long-term function wanes over time. Intraportal transplantation is associated with procedural risks, requires multiple donors, and does not afford routine biopsy. Stem cell technologies may require potential for retrievability, and graft removal by hepatectomy is impractical. There is a clear clinical need for an alternative, optimized transplantation site. The subcutaneous space is a potential substitute, but transplantation of islets into this site has routinely failed to reverse diabetes. However, an implanted device, which becomes prevascularized before transplantation, may alter this equation. Methods Syngeneic mouse islets were transplanted subcutaneously within Sernova Corp's Cell Pouch (CP). All recipients were preimplanted with CPs 4 weeks before diabetes induction and transplantation. After transplantation, recipients were monitored for glycemic control and glucose tolerance. Results Mouse islets transplanted into the CP routinely restored glycemic control with modest delay and responded well to glucose challenge, comparable to renal subcapsular islet grafts, despite a marginal islet dose, and normoglycemia was maintained until graft explantation. In contrast, islets transplanted subcutaneously alone failed to engraft. Islets within CPs stained positively for insulin, glucagon, and microvessels. Conclusions The CP is biocompatible, forms an environment suitable for islet engraftment, and offers a potential alternative to the intraportal site for islet and future stem cell therapies. The authors apply a new implanted subcutaneous cell pouch (CP) device in a mouse diabetes model. Mouse islets transplanted into the CP restore glycemic control with well respond to glucose challenge. CP may serve as a potential alternative to clinical intraportal islet transplantation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|